M&A Regulatory Due Diligence
Protecting investment through regulatory clarity
Regulatory risk can materially impact valuation, timelines and post-deal performance. We give investors and acquirers a clear view of risk before decisions are made.
50+
Years combined experience
100+
Life science projects delivered
20+
Global markets
01 - M&A RISK LANDSCAPE
Understanding regulatory risk in health and medical technology deals
Key risks we help you assess
Regulatory issues are often hidden until late in the deal process. We help investors, acquirers and boards identify material risks early, so decisions are based on a clear view of regulatory exposure.
Undisclosed compliance gaps
Gaps in technical documentation, clinical evidence or post-market surveillance can stay hidden until late-stage review or authority scrutiny.
Post-acquisition integration complexity
Bringing an acquired business into existing quality and regulatory systems can create delays, added cost and avoidable compliance issues.
Approval status risk
Market approvals may be narrower, older or more conditional than expected, affecting continuity, transition planning and future revenue.
Regulatory position and deal value
Certificates, clearances and approvals are commercial assets. Their status, scope and transferability can directly affect valuation.
“Regulatory maturity is a value lever not an overhead - regulatory is a financial asset.”
KEY STATISTICS
The impact of regulatory risk in M&A
Regulatory risk is a critical factor in health and medical technology transactions. These figures highlight its impact on valuation, cost and deal outcomes.
89%
of investors require regulatory intelligence in due diligence
+124%
Rise in EU MDR Notified Body certification costs
70%
of health and medical technology companies have withdrawn EU products due to MDR
43%
of healthcare M&A deals involved a distressed party
02 - OUR CAPABILITIES
Regulatory due diligence that supports confident deal decisions
What we deliver across the transaction lifecycle
We work alongside investors, acquirers and advisory teams to assess regulatory position, quantify risk and support decision-making throughout the deal process.
Technical due diligence and regulatory risk assessment
A detailed, product-level review of regulatory documentation, approvals and compliance position to identify risk, gaps and remediation requirements before completion.
Technical assessment
Technical file review and documentation assessment
Clinical evidence and data adequacy
Risk management and post-market surveillance review
Commercial and deal impact
Approval scope, status and transition requirements
Identification of compliance gaps and remediation effort
Impact on timelines, market access and deal value
Cross-jurisdictional
approval mapping
Clear view of approval status across UK, EU, US and other key markets, including scope, expiry and transition requirements.
Portfolio gap analysis
Review of product portfolios to identify overall regulatory exposure and prioritise areas requiring investment.
Investment readiness advisory
Support for investment or sale, with clear regulatory positioning and investor-ready documentation.
Regulatory risk assessment
Structured assessment of regulatory position, including likelihood of challenge, remediation effort and impact on market access.
Post-acquisition integration support
Planning integration into existing quality and regulatory systems to reduce disruption and maintain compliance.
Deal support and reporting
Clear, decision-ready reporting with ongoing support through management Q&A and transaction discussions.
03 - OUR APPROACH
How we support your deal team
Clear, structured input at every stage of the transaction
We work alongside your deal team to assess regulatory position, quantify risk and provide clear, decision-ready insight throughout the transaction.
1: Scope and data room review
Initial review of available documentation, including technical files, approvals, quality records and regulatory correspondence. Key gaps identified early.
2: Deep technical assessment
Structured review against applicable regulations across each product and market, covering classification, clinical evidence and compliance position.
3: Risk assessment and quantification
Findings translated into clear commercial terms, including remediation effort, timelines and impact on market access and revenue.
4: Reporting and deal support
Clear due diligence reporting for decision-makers, with ongoing support through management Q&A and transaction discussions.
5: Post-acquisition integration planning
Planning for integration into quality and regulatory systems, supporting compliance and continuity following completion.
04 - WHO WE SUPPORT
Supporting investors, acquirers and advisors
Who we work with across M&A transactions
We support a range of stakeholders involved in health and medical technology transactions, providing clear regulatory insight to support confident decision-making.
Private equity and venture capital
Independent regulatory assessment to support investment decisions and identify risk before capital is committed.
Health and medical technology companies
Support for companies preparing for investment or sale, with clear regulatory positioning and documentation.
Strategic acquirers
Assessment of regulatory position, compatibility and integration considerations for bolt-on and full acquisitions.
Accelerators and innovation partners
Support for portfolio companies requiring regulatory strategy, positioning and route-to-market planning.
Investment banks and advisors
Specialist regulatory input to support due diligence, information memoranda and transaction processes.
Family offices and private investors
Clear, practical guidance on regulatory risk and its impact on investment decisions and exit timelines.
Speak to the team
Get clear, practical guidance on your transaction and regulatory due diligence requirements.